Supernus to Host First Quarter 2015 Earnings Conference Call
April 21 2015 - 5:00PM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that the Company expects to report the
financial results for the first quarter of 2015 after 5:00 PM ET on
Tuesday, May 5, 2015.
Jack Khattar, President and Chief Executive Officer and Greg
Patrick, Chief Financial Officer, will host a conference call to
present the first quarter 2015 results on Wednesday, May 6, 2015 at
9:00 AM ET. Following the presentation, the call will be open for
questions.
A live webcast will be available at www.supernus.com. Following
the live call, a replay will be available on the Company's website
under the 'Investors' section. The webcast will be available on the
Company's website for 60 days following the live call.
Please refer to the information below for conference call
dial-in information. Callers should dial in approximately 10
minutes prior to the start of the call.
Conference dial-in: |
(877) 288-1043 |
International dial-in: |
(970) 315-0267 |
Conference ID: |
32101777 |
Conference Call Name: |
Supernus Pharmaceuticals 1Q 2015 Earnings
Conference Call |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR® (extended-release
topiramate). The Company is also developing several product
candidates to address large market opportunities in psychiatry.
These product candidates include SPN-810 for the treatment of
impulsive aggression in patients with ADHD in conjunction with
standard ADHD treatment and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Sep 2023 to Sep 2024